32 Included patients were matched for age, sex, race and ethnicity, cardiovascular diseases, DR severity (including PDR and DME status), history of tobacco use, body mass index, and hemoglobin A1c percentage
Besides your greens and pungent veggies, other sulfur-rich foods help keep glutathione levels up
And with so many effective tools available, now is an excellent time to consider making a change
less frequent injections or oral) Weight loss kinetics (slope of weight loss) Data in sub-populationsPayors have not said much about coverage decisions, which have historically been a challenge in this market, albeit with less effective drugs With so many eligible patients, payor budgets could be stretched in the near-term We will likely see restrictions & step-throughsThe reimbursement dynamic here is similar to curative modalities such as cell & gene therapy With patients switching insurance every few years, paying for preventative care does not mean reaping the benefits of future health I wrote about this here:This analysis has been focused on general (polygenic) obesity, but there is a separate pipeline for various genetically-driven obesities (monogenetic obesity) One player in this space is $RYTM which launched Imcivree for patients with 3 genetic deficiencies (POMC, PCSK1, LEPR)Overall, this market will be one to watch in 2023 & beyond as a driver of an industry reboundThat's all - if you enjoyed this, follow me @andrewpannu for more biotech charts, musings and breakdowns and consider sharing the below with your audienceObesity Market Overview A deep dive into the unmet need, competitive landscape and future of treatment: Skal man udskifte nogle Novo aktier med nogle af disse kandidater
B 13 , 709721 (2023)
